Valneva SE

Valneva announces resumption of trading of its ordinary shares on Euronext Paris

23 6 2022 09:00:00 提供 Nasdaq GlobeNewswire

Valneva Receives Positive CHMP Opinion for Marketing Authorization of its Inactivated COVID-19 Vaccine Candidate in Europe

23 6 2022 08:16:12 提供 Nasdaq GlobeNewswire

Valneva and Pfizer Enter into an Equity Subscription Agreement and Update Terms of Collaboration Agreement for Lyme Disease Vaccine Candidate VLA15

20 6 2022 00:00:00 提供 Nasdaq GlobeNewswire

Valneva Announces Settlement Agreement with the UK Government

15 6 2022 10:45:00 提供 Nasdaq GlobeNewswire

Valneva Provides Update on European Inactivated, Whole-Virus COVID-19 Vaccine Program VLA2001

10 6 2022 11:30:00 提供 Nasdaq GlobeNewswire

Valneva Joins Euronext’s Tech Leaders Index

08 6 2022 01:30:00 提供 Nasdaq GlobeNewswire

Valneva to Present on its Single-Shot Chikungunya Vaccine Candidate, Host Symposium at NECTM8

07 6 2022 10:45:00 提供 Nasdaq GlobeNewswire

Valneva to Present and Hold Investor Meetings at the Jefferies US Healthcare Conference

03 6 2022 10:45:00 提供 Nasdaq GlobeNewswire

Valneva Announces the Availability of Documentation for its Shareholder Meetings

02 6 2022 13:50:00 提供 Nasdaq GlobeNewswire

Valneva Appoints Dr. Thomas Decker and Dr. Michael Pfleiderer to its Scientific Advisory Board

31 5 2022 10:45:00 提供 Nasdaq GlobeNewswire